NCT06338696招募中不适用
Thailand Transthyretin Amyloid Cardiomyopathy Registry
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 105
- 试验地点
- 8
- 主要终点
- Rate of heart failure hospitalization
研究概览
简要总结
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age > 18 years.
- •All patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy) who have either symptomatic or asymptomatic must have evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of ≥ 12 mm and with at least one of the following criteria:
- •Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade ≥ 2 and/or H/CL (heart to contralateral lung) ratio > 1.5
- •Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade 1 and positive cardiac biopsy tissue confirmed which Congo red stain ≥ 4 sites
- •Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade 1 with positive non-cardiac biopsy tissue confirmed by Congo red stain
- •Abnormalities on CMR (Cardiac MRI) [Subendocardium LGE (late gadolinium enhancement) and/or elevated native T1 value and/or increased extracellular volume (ECV > 0.4)] with positive non-cardiac and/or cardiac tissue biopsy confirmed by Congo red stain
排除标准
- •Diagnosed with amyloidosis caused by proteins other than transthyretin (light chain Amyloidosis, etc.)
- •Diagnosed with secondary amyloidosis
结局指标
主要结局
Rate of heart failure hospitalization
时间窗: 3 years
Rate of death
时间窗: 3 years
次要结局
- Transthyretin (ATTR) amyloidosis medication(3 years)
研究者
Rungroj Krittayaphong
Professor
Mahidol University
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
不适用
Bronx Transthyretin Amyloid Cardiomyopathy DatabaseTransthyretin Cardiac AmyloidosisTransthyretin Amyloid CardiomyopathyNCT06257485Montefiore Medical Center476
已完成
早期 1 期
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic StenosisTransthyretin AmyloidosisTransthyretin Amyloid CardiomyopathyTransthyretin Cardiac AmyloidosisAortic StenosisNCT04899180Mayo Clinic4
终止
不适用
Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release SurgeryTransthyretin AmyloidosisCarpal Tunnel SyndromeNCT04611204University Hospital, Toulouse6
招募中
不适用
Orthopaedic Specimen Pathology and Early Diagnosis of ATTR Cardiopathy (ATTR-ORTHO)ATTR AmyloidosisCardiopathyLumbar Spine StenosisHip ProsthesisKnee ProsthesisCarpal Tunnel SyndromeNCT06367842Institut Mutualiste Montsouris150
已完成
不适用
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown EtiologyTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM)NCT03842163Pfizer812